Cocrystal Pharma Inc COCP
📋 Company Profile
| Industry | Pharmaceuticals |
| Country | US |
| Exchange | NASDAQ NMS - GLOBAL MARKET |
| Currency | USD |
| IPO Date | 2018-03-12 |
| Shares Out. | 13,790,000 |
| Website | cocrystalpharma.com/ ↗ |
| Phone | 13023513367 |
| Employees | 10 |
| Revenue | $225,000 |
| Gross Profit | $225,000 |
| Net Income | -$2.3M |
| Free Cash Flow | -$7.6M |
| Total Assets | $7.4M |
| Total Liabilities | $3.3M |
| Equity | $4.1M |
About Cocrystal Pharma Inc
Cocrystal Pharma Inc is a biotechnology company discovering and developing novel antiviral therapeutics that target the replication machinery of influenza viruses, hepatitis C viruses, and noroviruses. It employs structure-based technologies and Nobel Prize-winning expertise to create first and in-class antiviral drugs. It is developing CC-31244, an investigational, oral, broad-spectrum replication inhibitor called a non-nucleoside inhibitor (NNI). The company has one reportable and operating segment dedicated to the research and development company's novel orally administered antiviral influenza candidate. The company has pipeline products for diseases like : Influenza, Norovirus, Coronavirus, Respiratory Viruses, and Hepatitis C.
Cocrystal Pharma Inc is a publicly traded company under the ticker symbol COCP on the NASDAQ NMS - GLOBAL MARKET, operating in the Pharmaceuticals industry. Quotes and metrics shown here are sourced from public market data and refreshed regularly.
📊 Analyst Ratings
7 analysts (2026-07-01)